The dorsal root ganglion (DRG) is a cluster of sensory neuron cell bodies located on the dorsal root of each spinal nerve, just outside the spinal cord. Each spinal segment has paired DRGs (31 pairs total in humans: 8 cervical, 12 thoracic, 5 lumbar, 5 sacral, 1 coccygeal). DRG neurons are pseudo-unipolar, with a single axon that bifurcates: one branch extends peripherally to sensory receptors in skin, muscle, and viscera; the other extends centrally into the spinal cord dorsal horn. The DRG contains the cell bodies of ALL primary sensory neurons conveying touch, temperature, proprioception, and nociception from the body.
Think of the DRG as a regional post office for sensory information. The building sits just outside the central sorting facility (the spinal cord), not inside it. Each sensory neuron is like a postal worker with an extremely long, branching route: one arm of the route goes out to homes and businesses in the neighborhood (peripheral tissues), collecting letters (sensory signals) from mailboxes (receptors). The other arm runs back to the central sorting facility to deliver those letters. The worker's actual office—where they keep their desk, files, and supplies (the cell body with nucleus and protein synthesis machinery)—is in this regional building (the DRG), NOT at either end of their route.
This location matters enormously: if the regional post office catches fire (inflammation at the DRG), EVERY postal route running through that building gets disrupted. All the workers become hypersensitive, some start sending false alarm letters even when there's no mail to collect (spontaneous activity), and the pain signals from their entire district get amplified. This is why a single inflamed DRG can cause radiating pain across an entire dermatome—the whole postal district served by that office is affected.
DRG Neuronal Classification:
The DRG contains three main sensory neuron populations, classified by axon diameter, myelination, and conduction velocity:
-
Large A-beta neurons (30-70 μm/s): Heavily myelinated, large diameter axons. Mediate touch, vibration, and proprioception via mechanoreceptors (Merkel cells, Pacinian corpuscles, muscle spindles). Cell bodies are large (40-80 μm diameter).
-
Medium A-delta neurons (12-30 μm/s): Thinly myelinated, medium diameter. Mediate fast, sharp pain and cold sensation via TRPA1, TRPV1, and mechanical nociceptors. Cell bodies 25-40 μm diameter.
-
Small C-fibres (<1 μm/s): Unmyelinated, small diameter. Mediate slow, burning pain, warmth, itch, and visceral sensation via TRPV1, TRPA1, MrgprX receptors. Cell bodies 15-25 μm diameter. Synthesize neuropeptides (Substance P, CGRP, somatostatin).
Molecular Architecture:
Each DRG neuron expresses a distinct receptor repertoire on its peripheral terminal:
- Thermal TRP channels: TRPV1 (>43°C heat), TRPV2 (>52°C), TRPM8 (<25°C cold), TRPA1 (<17°C noxious cold, chemical irritants)
- Mechanoreceptors: Piezoelectric channels (Piezo1, Piezo2), ASIC (acid-sensing ion channels)
- Chemoreceptors: Purinergic (P2X3), bradykinin (B2), histamine (H1), NGF (TrkA Receptor)
- Voltage-gated channels: Nav1.8 (TTX-resistant sodium channel—critical for nociceptor action potentials), Kv1.2 (potassium channel—repolarization)
Peripheral Sensitization Cascade:
During tissue injury and inflammation, the DRG neuron undergoes profound molecular changes:
graph TD
A[Tissue Injury] --> B["Inflammatory Soup: PGE2, bradykinin, NGF, TNF-α"]
B --> C[NGF binds TrkA on C-fibre terminal]
C --> D[TrkA retrograde transport to DRG cell body]
D --> E[Transcriptional Changes]
E --> F["↑Nav1.8, ↑TRPV1, ↑Substance P, ↑CGRP synthesis"]
F --> G["↑Receptor insertion in peripheral terminal"]
G --> H[Lowered Activation Threshold]
B --> I[PGE2 binds EP receptors]
I --> J[PKA activation]
J --> K[Phosphorylation of TRPV1, Nav1.8]
K --> H
H --> L[Peripheral Sensitization]
L --> M[Spontaneous Activity]
L --> N[Mechanical Allodynia]
L --> O[Thermal Hyperalgesia]
NGF-TrkA Pathway (Central to DRG Sensitization):
- NGF released from injured tissue → binds TrkA Receptor on nociceptor terminal
- NGF-TrkA complex endocytosed → retrograde axonal transport (dynein motors) → reaches DRG cell body
- TrkA activates: PI3K/Akt → mTOR → protein synthesis; MAPK/ERK → CREB phosphorylation → gene transcription
- Upregulated genes: Nav1.8 (3-5 fold), TRPV1 (2-4 fold), Substance P (4-6 fold), CGRP (3-5 fold), BDNF
- New channels/peptides transported anterogradely to peripheral and central terminals
- Result: Lowered threshold (activation by normally innocuous stimuli) + increased spontaneous firing (ectopic discharge from DRG)
Ectopic Activity Generation:
In chronic pain states, DRG neurons generate spontaneous action potentials independent of peripheral input:
- Increased Nav1.8 expression → depolarized resting membrane potential (-65 mV → -55 mV)
- Downregulation of Kv1.2 potassium channels → reduced repolarization capacity
- Result: Oscillatory depolarizations crossing threshold without external stimulus
- This ectopic activity perceived as spontaneous, ongoing pain
Viral Latency Mechanism (Herpes Zoster):
- Varicella-zoster virus (VZV) infects skin during primary infection (chickenpox) → viral particles retrogradely transported to DRG
- VZV establishes latent infection in DRG neuron nuclei (non-replicating, genome maintained as episome)
- During reactivation (immune suppression, stress): viral replication → anterograde transport → dermatomal vesicular rash
- Inflammatory response in DRG → persistent nociceptor sensitization → neuropathic pain (postherpetic neuralgia)
Why the DRG Is a Critical Intervention Point:
The DRG represents the anatomical bottleneck for ALL sensory information from the periphery. Because the cell bodies of nociceptors reside here (not in peripheral tissues or spinal cord), interventions targeting the DRG can modulate pain at its source. This is especially relevant in radicular pain syndromes where DRG inflammation or compression is the primary driver.
Clinical Conditions Involving the DRG:
-
Sciatica and Lumbar Radiculopathy:
- Herniated disc or foraminal stenosis → mechanical compression of L4-S1 DRG
- Compression → local ischemia + inflammatory mediator release (TNF-α, IL-1β, PGE2)
- DRG neurons become hyperexcitable → dermatomal pain distribution (L5: lateral leg/dorsal foot; S1: posterior leg/plantar foot)
- Clinical markers: Straight leg raise test positive, dermatomal sensory changes, decreased ankle reflex (S1)
-
Herpes Zoster (Shingles):
- VZV reactivation in DRG → unilateral dermatomal vesicular rash
- Inflammatory destruction of DRG neurons → peripheral sensitization + central sensitization
- Postherpetic neuralgia: Persistent neuropathic pain in >10% of patients (risk increases with age: 50% in >60 years)
- Pain phenotype: Spontaneous burning + mechanical allodynia in affected dermatome
-
Complex Regional Pain Syndrome (CRPS):
- Post-traumatic neuroinflammation may involve DRG sensitization
- Elevated CGRP and Substance P release from sensitized DRG neurons → neurogenic inflammation (vasodilation, edema, mast cell degranulation)
- Autonomic dysregulation: Sympathetic sprouting in DRG (normally absent) → sympathetic-sensory coupling
-
Fibromyalgia and Widespread Pain:
- Emerging evidence: Systemic inflammatory mediators may sensitize DRG neurons across multiple spinal levels
- Nerve growth factor (NGF) elevated in fibromyalgia plasma → potential widespread TrkA activation in DRG
- Anti-NGF antibodies (tanezumab) show efficacy but CNS side effects limit use
DRG Injections in cPNI Practice:
Leo Pruimboom and colleagues use targeted DRG injections with:
- Traumeel: Multi-component biological anti-inflammatory (arnica, calendula, belladonna, etc.)
- Lactic acid 5% solution: Creates temporary acidic environment → ASIC3 activation paradoxically reduces nociceptor excitability via desensitization
- PRP (platelet-rich plasma): Growth factors (PDGF, TGF-β) promote tissue repair + anti-inflammatory resolvins
Mechanism of Lactic Acid Injection:
- Low pH (4.5-5.0) → activates ASIC channels on DRG neurons
- Initial burst of activity → rapid desensitization (channel inactivation)
- Tachyphylaxis: Reduced responsiveness to subsequent pain stimuli for 4-12 weeks
- Clinical application: Segmental injections for radicular pain, headaches (cervical DRG), pelvic pain (sacral DRG)
Metamodel Connections:
- 5 plus 2 metamodel: DRG sensitization represents a critical "switch" in pain chronification. Intervention here (Metamodel 2: Reduce inflammation) prevents central sensitization (Metamodel 3: Brain changes)
- Selfish brain theory: The DRG, like the brain, can become "selfish" in chronic pain—spontaneous activity consumes ATP, local hypoxia → HIF-1 activation → further inflammatory signaling. A positive feedback loop.
- Evolutionary mismatch: Modern sedentarism → chronic DRG compression (prolonged sitting compresses lumbar/sacral DRG). Hunter-gatherers had positional variety that prevented sustained compression.
Exam-Relevant Clinical Thresholds:
- DRG intervention level selection: Match dermatomal pain distribution (L5 sciatica → L5 DRG injection)
- Timing: Acute radiculopathy (<6 weeks): High success rate with anti-inflammatory DRG injection. Chronic (>6 months): Central sensitization may dominate—peripheral intervention alone insufficient.
- Red flags: Cauda equina syndrome (bladder/bowel dysfunction, saddle anesthesia) → surgical emergency, NOT injection candidate
- 31 pairs of DRGs in humans (8 cervical, 12 thoracic, 5 lumbar, 5 sacral, 1 coccygeal)
- DRG located in intervertebral foramen, NOT in spinal canal
- Pseudo-unipolar morphology: Single axon bifurcates into peripheral and central branches
- A-beta fibres (30-70 m/s): Touch, vibration, proprioception; A-delta (12-30 m/s): Fast pain, cold; C-fibres (<1 m/s): Slow pain, warmth, itch
- Nav1.8 sodium channel is TTX-resistant, expressed almost exclusively in DRG nociceptors—critical drug target
- NGF-TrkA pathway increases Nav1.8 expression 3-5 fold during inflammation
- Substance P and CGRP synthesized in 40-50% of DRG C-fibres (peptidergic population)
- Herpes zoster reactivation rate: 1-3 per 1000 person-years; lifetime risk 10-30%
- DRG neurons have NO blood-brain barrier protection—accessible to systemic inflammatory mediators
- Ectopic DRG activity accounts for 30-60% of spontaneous pain in neuropathic conditions
- Lactic acid injections create pH 4.5-5.0 microenvironment → ASIC3 desensitization lasting 4-12 weeks
- Each DRG innervates a specific dermatome: C6 (thumb/index finger), L5 (lateral leg/big toe), S1 (lateral foot/small toe)
- spinal nerve — DRG is located on dorsal root immediately before dorsal and ventral roots merge to form spinal nerve
- dorsal horn — DRG central axons enter spinal cord and synapse in laminae I-V of dorsal horn
- sensory neurons — DRG contains the cell bodies of ALL primary afferent sensory neurons from the body
- nociceptors — Nociceptive A-delta and C-fibre cell bodies exclusively located in DRG
- C-fibres — Unmyelinated slow pain fibres; cell bodies in DRG synthesize Substance P and CGRP
- A-delta fibres — Thinly myelinated fast pain fibres; DRG cell bodies express TRPV1 and TRPA1
- A-beta fibres — Large myelinated mechanoreceptive fibres; largest DRG cell bodies (40-80 μm)
- Substance P — Neuropeptide synthesized in 40-50% of DRG C-fibres; promotes neurogenic inflammation and central sensitization
- CGRP — Calcitonin gene-related peptide co-released with Substance P from DRG terminals; potent vasodilator
- peripheral sensitization — Inflammatory mediators lower DRG nociceptor threshold via TrkA/NGF pathway and direct receptor phosphorylation
- central sensitization — Persistent DRG hyperactivity (ectopic discharge) drives spinal cord wind-up and long-term potentiation
- radicular pain — DRG compression or inflammation causes dermatomal pain pattern (e.g., sciatica from L5/S1 DRG)
- sciatica — Lumbar/sacral DRG inflammation from disc herniation; classic L5 or S1 dermatomal distribution
- herpes zoster — VZV establishes latent infection in DRG neurons; reactivation causes shingles and postherpetic neuralgia
- spinal injection — Targeted DRG injection with Traumeel, lactic acid, or PRP modulates inflammation at pain source
- dermatomal distribution — Each DRG corresponds to specific skin territory; C6 DRG → thumb/index finger sensation
- nerve growth factor — NGF binds TrkA on DRG nociceptors → retrograde signaling → upregulation of Nav1.8, TRPV1, neuropeptides
- TRP channels — TRPV1, TRPA1, TRPM8 expressed on DRG peripheral terminals; detect heat, chemical irritants, cold
- neurogenic inflammation — CGRP and Substance P released from DRG terminals cause vasodilation, plasma extravasation, mast cell degranulation
- neuropathic pain — DRG neuron hyperexcitability (spontaneous activity, reduced threshold) major contributor to chronic neuropathic pain
- inflammation — TNF-α, IL-1β, PGE2 in DRG microenvironment sensitize neurons via PKA/PKC phosphorylation of ion channels
- Nav1.8 — TTX-resistant voltage-gated sodium channel; primary action potential generator in DRG nociceptors; upregulated 3-5 fold by NGF
- TRPV1 — Heat and capsaicin receptor; expressed on 30-40% of DRG C-fibres; sensitized by PGE2 and NGF signaling
- TrkA Receptor — High-affinity NGF receptor on nociceptive DRG neurons; retrograde signaling drives sensitization cascade
- ASIC — Acid-sensing ion channels on DRG neurons; activated by tissue acidosis (pH <6.5) and lactic acid injections
- Piezoelectric channels — Mechanically-gated channels (Piezo2) on DRG mechanoreceptors; transduce touch and proprioception
- Complex Regional Pain Syndrome — CRPS may involve sympathetic sprouting in DRG (normally absent) → sympathetic-sensory coupling
- fibromyalgia — Systemic elevation of NGF may sensitize DRG neurons across multiple levels → widespread pain
- allodynia — DRG sensitization lowers threshold → normally innocuous stimuli (light touch via A-beta) perceived as painful
- hyperalgesia — Enhanced pain response from sensitized DRG nociceptors; reduced thermal/mechanical threshold
- ectopic activity — Spontaneous DRG discharge independent of peripheral input; accounts for 30-60% of neuropathic pain
- blood-brain barrier — DRG neurons lack BBB protection; accessible to systemic inflammatory cytokines and immune cells
- autonomic nervous system — Sympathetic fibres may invade DRG in pathological states (normally absent) → sympathetically-maintained pain